Contact Us

Adderall
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Adderall

Adderall Side Effect Attorneys
CLICK HERE FOR OUR ADDERALL INFORMATION PACKAGE

Adderall Side Effects May Lead To Sudden Death Lawsuits

Adderrall | Lawyers, Lawsuits | Side Effects: Sudden death, Serious Cardiovascular Problems, Heart Attacks

The FDA awarded Shire Pharmaceuticals approval for Adderall on November 8, 2002. Adderall is used by approximately 700,000 Americans and is one of the most popular drugs for people with Attention Deficit Hyperactivity Disorder (ADHD). Adderall contains amphetamine and dextroamphetamine, which are both stimulants. Shire Pharmaceuticals Group PLC sold $759 million of Adderall XR in the U.S. and roughly $10 million in Canada in 2004.

On February 9, 2005, Health Canada, the Canadian drug regulatory agency, suspended sales of Adderall in Canada. Adderall is a controlled release amphetamine used to treat patients with Attention Deficit Hyperactivity Disorder (ADHD). The Canadian action was based on U.S. post-marketing reports of sudden deaths in pediatric patients.

In a news release, Health Canada said, "the incidence of serious adverse reactions leading to death was higher in" the extended release and earlier formulations of Adderall, when added together, than in other drugs in the same class. Of the 20 deaths reported in patients taking Adderall, 12 were from strokes, and two were in children, Health Canada said.

FDA is evaluating Adderall Adverse Effects

On January 3, 2006, the Food and Drug Administration asked its standing committee of risk-management advisers to review reports of heart-related complications in children and adults using attention deficit disorder drugs. U.S. and Canadian regulators have been looking in the past few years at the probable heart risk of attention-deficit drugs, which are stimulants used to improve concentration.

The three main ADHD drugs that will be reviewed at the February 9, 2006 FDA review meeting include Adderall, Concerta, and Strattera.

In August 2005, Health Canada allowed Shire Pharmaceuticals to begin selling Adderall again.

On February 9, 2006, Federal science advisers voted narrowly on proposing the most serious type of warning labels for Adderall, Concerta, Ritalin and all other ADHD drugs. The Food Drug Administration (FDA) Committee voted 8-7, recommending the adding of black box safety warnings to ADHD drugs. Doctors prescribe ADHD drugs to approximately 2 million children and 1 million adults a month.

The FDA data suggested a link between ADHD drugs and an increased risk of sudden death and serious cardiovascular problems, including heart attacks. Dr. Steve Nissen told his colleagues they should push for the black box warning on the ADHD drugs' packages. A federal health official said Thursday that there was a strong possibility the drugs may be linked to the deaths of 25 people.

The deaths took place between 1999 and 2003, based upon a FDA report. Nineteen of them involved children. The report also detailed 54 cases of severe cardiovascular problems, including heart attack, stroke, hypertension, palpitations and arrhythmia, in adults and children being treated with ADHD drugs.

Adderall, Concerta, Ritalin and other ADHD drugs Sales Increase

Sales spike from $759 million to $3.1 billion in 2004, according to IMS Health, a pharmaceutical information and consulting firm.

Legal Help For Victims Affected By Adderall

If you or a loved one took Adderall and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney or call us at 1-800-YOURLAWYER (1-800-968-7529).



 

AdderallRSS Feed

Health Canada Issues Actos Bladder Cancer Warning, Announces Label Update

May 21, 2012 | Parker Waichman LLP
Doctors and patients in Canada have been warned that taking Actos for more than a year may increase the risk of developing bladder cancer.  In an alert issued last month, Health Canada said that Takeda Pharmaceuticals, the maker of Actos, had agreed to update the drug's Canadian label to warn of the potential for Actos bladder cancer side effects.According to Health Canada: Actos should not be used by patients who have or have had bladder cancer, or those who have blood or red color in...

ADHD Drug Study Finds Heart Death Risks for Kids, But FDA Says Recommendations Won't Change

Jun 16, 2009 | Parker Waichman LLP
While a new study has found that stimulant medications used to treat attention-deficit hyperactivity disorder (ADHD) may increase the risk of sudden cardiac death in children, the Food & Drug Administration (FDA) is not changing its recommendations on the way such drugs are prescribed.  According to a posting on its website, the agency is asserting that the study had "limitations" that makes it difficult to draw conclusions about the drugs' risks.Labeling for drugs like Ritalin,...

ADHD Study Stirs Controversy

Mar 27, 2009 | Parker Waichman LLP
The safety and effectiveness of medications used to treat attention-deficit hyperactivity disorder (ADHD) are being questioned with the release of new study data that shows such drugs to be ineffective - and possibly harmful - in the long term.  According to The Washington Post, the findings are also raising questions about the conduct of some involved in the research, because they are very different than initial findings that were released in 1999. The study, known as the Multimodal...

ADHD Study Stirs Controversy

Mar 27, 2009 | Parker Waichman LLP
The safety and effectiveness of medications used to treat attention-deficit hyperactivity disorder (ADHD) are being questioned with the release of new study data that shows such drugs to be ineffective - and possibly harmful - in the long term.  According to The Washington Post, the findings are also raising questions about the conduct of some involved in the research, because they are very different than initial findings that were released in 1999. The study, known as the Multimodal...

American Children Take the Most Psychotropic Drugs

Sep 26, 2008 | Parker Waichman LLP
A new study reports that American children are about three times likelier to be prescribed psychotropic medications than children in Europe.  The study states that the differences may be attributable to regulatory practices and cultural beliefs about the role of medication in emotional and behavioral problems.Julie Zito led the team comprised of researchers from the U.S., Germany, and the Netherlands.  The group investigated prescription levels in the three countries.  Zito...

More Adderall News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo